• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

预防新生儿戒断综合征和治疗农村地区阿片类药物使用的年轻女性的成瘾问题。

Averting neonatal abstinence syndrome and treating addiction among rural, opioid-using young women.

机构信息

Department of Family and Community Medicine, Meharry Medical College, Nashville, Tennessee, USA.

Department of Health Behavior & Society, University of Kentucky, Lexington, Kentucky, USA.

出版信息

Am J Addict. 2022 Sep;31(5):441-446. doi: 10.1111/ajad.13299. Epub 2022 May 9.

DOI:10.1111/ajad.13299
PMID:35535402
Abstract

BACKGROUND AND OBJECTIVES

America's opioid epidemic has spawned an epidemic of neonatal abstinence syndrome (NAS). Studies have not tested approaches to promoting contraceptive services for women with opioid use disorder (OUD) along with treatment for this disorder. This pilot study examined the promotion of medication for OUD (MOUD) treatment and contraception use, primarily long-acting reversible contraception (LARC), for women with OUD.

METHODS

In Appalachia, a peer-delivered contraception and MOUD promotion intervention was delivered to a sample of 30 women with OUD. Primary outcomes were attendance of initial appointments to receive MOUD and counseling about contraceptive options. Peer recovery coaches also offered to help the women schedule appointments and attend the appointment with them or give them a ride if necessary and requested by the patients.

RESULTS

Two-thirds experienced all seven symptoms of opioid dependence. Within 30 days of a brief counseling session, over one-half of the women (56.7%) were referred to MOUD, with all of them initiating treatment within 30 days. Just under one-half of the women (46.7%) were referred to a contraception consultation, with 85.7% of those receiving a LARC implant.

DISCUSSIONS AND CONCLUSIONS

Study findings indicate the potential efficacy of a single-session, peer-delivered counseling intervention for linking women with OUD and at high risk of unintended pregnancy to MOUD and to services that provide women with highly reliable contraceptives.

SCIENTIFIC SIGNIFICANCE

This study is unique in exploring the efficacy of linking high-risk opioid-using women to contraceptive options and treatment for MOUD to prevent NAS.

摘要

背景和目的

美国的阿片类药物泛滥已引发新生儿戒断综合征(NAS)泛滥。研究尚未检验过为患有阿片类药物使用障碍(OUD)的女性提供避孕服务以及治疗这种疾病的方法。这项试点研究检验了为患有 OUD 的女性提供促进 OUD 药物治疗(MOUD)和避孕措施(主要是长效可逆避孕法,LARC)的方法。

方法

在阿巴拉契亚地区,为 30 名患有 OUD 的女性提供了由同伴提供的避孕和 MOUD 促进干预措施。主要结局是参加 MOUD 初始预约和咨询避孕选择的情况。同伴康复教练还主动提出帮助女性安排预约并陪她们参加预约,或者在患者要求的情况下开车送她们去。

结果

三分之二的女性经历了所有七种阿片类药物依赖症状。在简短的咨询课程后 30 天内,超过一半的女性(56.7%)被转介到 MOUD,其中所有人都在 30 天内开始治疗。略低于一半的女性(46.7%)被转介到避孕咨询,其中 85.7%的人接受了 LARC 植入。

讨论和结论

研究结果表明,单次、同伴提供的咨询干预措施有潜力将患有 OUD 且有高意外怀孕风险的女性与 MOUD 以及为女性提供高度可靠避孕措施的服务联系起来。

科学意义

这项研究独特之处在于探索了将高危阿片类药物使用者女性与避孕选择和 MOUD 治疗联系起来以预防 NAS 的疗效。

相似文献

1
Averting neonatal abstinence syndrome and treating addiction among rural, opioid-using young women.预防新生儿戒断综合征和治疗农村地区阿片类药物使用的年轻女性的成瘾问题。
Am J Addict. 2022 Sep;31(5):441-446. doi: 10.1111/ajad.13299. Epub 2022 May 9.
2
A retrospective, observational study on medication for opioid use disorder during pregnancy and risk for neonatal abstinence syndrome.一项关于孕期阿片类药物使用障碍用药及新生儿戒断综合征风险的回顾性观察研究。
Fam Pract. 2022 Mar 24;39(2):311-315. doi: 10.1093/fampra/cmab121.
3
Increasing access to family planning services among women receiving medications for opioid use disorder: A pilot randomized trial examining a peer-led navigation intervention.增加接受阿片类药物使用障碍治疗的女性获得计划生育服务的机会:一项试点随机试验,研究了一种由同伴主导的导航干预措施。
J Subst Abuse Treat. 2021 Jul;126:108318. doi: 10.1016/j.jsat.2021.108318. Epub 2021 Feb 4.
4
Maternal opioid use disorder and infant mortality in Wisconsin, United States, 2010-2018.美国威斯康星州 2010-2018 年产妇阿片类药物使用障碍与婴儿死亡率
Prev Med. 2024 Apr;181:107914. doi: 10.1016/j.ypmed.2024.107914. Epub 2024 Feb 24.
5
Addressing opioid use disorder among rural pregnant and postpartum women: a study protocol.解决农村孕妇和产后妇女阿片类药物使用障碍问题:一项研究方案。
Addict Sci Clin Pract. 2020 Oct 31;15(1):33. doi: 10.1186/s13722-020-00206-6.
6
Sex and female empowerment (SAFE): A randomized trial comparing sexual health interventions for women in treatment for opioid use disorder.性与女性赋权(SAFE):一项比较针对阿片类药物使用障碍女性患者性健康干预措施的随机试验。
Drug Alcohol Depend. 2021 Apr 1;221:108634. doi: 10.1016/j.drugalcdep.2021.108634. Epub 2021 Feb 17.
7
The Pregnancy Recovery Center: A women-centered treatment program for pregnant and postpartum women with opioid use disorder.妊娠康复中心:一个以妇女为中心的治疗项目,针对患有阿片类药物使用障碍的孕妇和产后妇女。
Addict Behav. 2018 Nov;86:124-129. doi: 10.1016/j.addbeh.2018.05.016. Epub 2018 May 24.
8
Contraception claims by medication for opioid use disorder prescription status among insured women with opioid use disorder, United States, 2018.医保覆盖人群中,患有阿片类药物使用障碍的女性,其处方药物的避孕功效声明,美国,2018 年。
Contraception. 2023 Jan;117:67-72. doi: 10.1016/j.contraception.2022.09.129. Epub 2022 Oct 12.
9
Medications for opioid use disorder in pregnancy in a state women's prison facility.孕期女性州立监狱中阿片类药物使用障碍的药物治疗。
Drug Alcohol Depend. 2020 Sep 1;214:108159. doi: 10.1016/j.drugalcdep.2020.108159. Epub 2020 Jul 7.
10
Long-acting reversible contraceptives (LARCs) as harm reduction: a qualitative study exploring views of women with histories of opioid misuse.长效可逆避孕措施(LARCs)作为减少伤害的方法:一项探索有阿片类药物滥用史的女性观点的定性研究。
Harm Reduct J. 2021 Aug 4;18(1):83. doi: 10.1186/s12954-021-00532-1.

引用本文的文献

1
A Pilot Randomized Controlled Trial Evaluating Peer Recovery Coaches for Addiction Recovery Among Indigenous Americans.一项评估同伴康复教练对美国原住民成瘾康复效果的试点随机对照试验。
J Am Psychiatr Nurses Assoc. 2025 Feb 22:10783903251319789. doi: 10.1177/10783903251319789.
2
Attitudes Toward Medication for Opioid Use Disorder Among Pregnant and Postpartum Women and People Seeking Treatment.孕妇和产后妇女及寻求治疗者对阿片类药物使用障碍药物治疗的态度。
J Addict Med. 2023;17(3):356-359. doi: 10.1097/ADM.0000000000001113. Epub 2022 Dec 13.